Early HIT Diagnostics Retham Technologies is developing HITDx, an in vitro diagnostic assay aimed at early and accurate near-patient HIT diagnosis, presenting a clear sales angle to hospitals seeking faster, more reliable testing to improve patient outcomes.

Cost Reduction Focus Current HIT testing relies on PF4 ELISAs with high false positives and SRA is limited by access and cost; HITDx offers potential to reduce unnecessary non-heparin anticoagulants and associated bleeding risks, appealing to hospital procurement and budgeting teams.

Clinical Impact By enabling timely therapy decisions, HITDx can shorten hospital stays and reduce complications from HIT, which can be a compelling value proposition for risk management, patient safety officers, and clinicians.

Early Stage Partnerships With a small team and early funding, opportunities exist to partner with academic medical centers, contract research organizations, or regional health systems for pilot studies, validation, and co-development opportunities.

Tech and Compliance Readiness The technology stack and regulatory-conscious approach suggest readiness to align with hospital IT ecosystems and quality/regulatory standards, easing integration considerations for near-patient testing deployment.